Kansaru prostate lati nyau feere je ɓuri nyaɗugo ha nder worɓe ha nder duniyaru fu, be limtol nyauɓe keese milionji 1.276 je matinama ha 2018, je ɗon no holla 7.1% nyauɓe fu ha nder worɓe.
Limgal mayde ngam nyau prostate lati bo'o masin, be limgal mayde 37,005 ha nder duniyaru fu ha 2018.
Amma, limtol mayde ɗon saanja masin ha wakkere feere, be Waila Afirka je ɗon mari sababu jowi je ɓuri maunugo ngam nyau prostate ha nder duniyaru, be Nigeria je ɗon mari ummatore be njawdi ɓurdum ha wakkere ndu.
Ha Nigeria, nyau cancer prostate lati nyau cancer je ɓuri nyaɗugo e je ɗon mbarda yimɓe fu ha nder worɓe, be limtol nyauɓe 32.8 be mayde 16.3 ha 100,000 worɓe.
Ndu ɓuri limtol mayde ha Waila Amerika nde ɗiɗi.
Lartol nyau ndu be wakati, dabareji ngam lartol e tawugo nyau, e limtol e matinolji nyauɓe ɗon usta limtol mayde ha Nigeria.
Ha Lesɗe America, nyau prostate lati bana nyau feere je ɗon waɗa mayde ha nder worɓe, be ɓadi worɓe 40,0000 je ɗon maaya ngam nyau ndu kala nduuɓu.
Limgal mayde ngam nyau prostate ɗon usta seɗɗa diga fuɗɗam hitaande 1990s, amma lati larulaji jam ɓaandu je ɗon mari sembe.
Ha nder fu, nyau prostate lati nyau je ɗon mbara, ɓurna fu ha wakkereji je ɗon mari dabare hurgol be lartolji nyau.
Amma, tawugo be hurgol be wakati footi ɓesda batte e ustugo limtol mayde.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Wurtinol: jam ɓaandu']
['Web site ndu ɗon hokka ngam ekkitol be matinolji tan e wala bana hokkugo feeloji do jam ɓaandu mala kuɗe.']
["Matinolji je ɗon hokka footay huwire ngam lartol mala hurgol nyau mala nyauji, e ɓe'en je ɗon ɗaɓɓita feelo lekki sey ɓe laara do lekkitajo je mari jaawal."]
['Ladde ngam matinolji je ɗon wurtina jaawabuji do emmolji, lati bana je ɗon mari limgal je ɗon larni nyauɓe.']
['Footi a ɗaɓɓita jaahargal do lekkitajo ma mala goɗɗo dokkoowo jam ɓaandu je mari daama do nyau ma. Taa meema jaahargal do lekkitajo mala neeɓu ɗaɓɓugo ndu ngam ko a jaangi ha do wakkere web ndu. To a tammi a footi mara nyau jaawal, ewna 911 mala yah ha suudu jaawal je ɓadi ma be law. Wala alaka lekkitajo be nyauɗo je ɗon wangina gal wakkere web ndu mala huwugo ndu. BioMedLib mala huwooɓe ma, mala goɗɗo je ɗon walli ha wakkere web ndu, ɗon wolwa, ɗon holla mala ɗon nufa, do matinolji je ɗon hokka ha nder ndu mala huwugo ndu.']
['Wurtinol hakke: copyright']
["Digital Millennium Copyright Act je 1998, 17 U.S.C. § 512 (DMCA) ɗon hokka dabare ngam marɓe hakkeji je ɗon hoola yo'o kujeji je ɗon wangi ha do Internet ɗon luuta hakkeji maɓɓe do dooka hakkeji je Lesɗe America. "]
["To a ɗon nuɗɗini be nuɗɗinki boɗɗum yo'o kujeji mala kujeji je ɗon no wondi be web site mala kuɗe amin ɗon meema ceede je mari, an (mala wakili'en ma) footi nelda amin matinol je ɗon emma ngam ittugo kujeji mala kujeji, mala haɗugo heɓugo ndu. "]
['Matinolji sey nelda be ɗerewol gal emayel (laaru "Contact" ngam emayel).']
["DMCA yiɗi matinolji je ɗon bana ɗon larni matinolji je ɗon tokkitini: (1) tindol kugal je mari hakkeji je ɗon larni je ɗon tokkitini; (2) tindol kuje je ɗon larni je ɗon larni e matinolji je ɗon mari hakkeji je ɗon mari haaje ngam en heɓta kuje man; (3) matinolji ngam a wonda be ma, be lamar, lamba telefon be lamar email; (4) matinol je a holli a ɗon hoola be goonga yo'o kuje je ɗon no ɗon holla bana ɗon larni wala jaɓol marɗo hakkeji, mala wakiilijo maako, mala gal kugal dookaaji; "]
['(5) matinolji je on windi, je on windi ha les bone seedugo fewre, je matinolji ha nder matinolji man lati goonga e je on mari baawɗe ngam aynugo hakkeji je mbiyotto ɗon luuta;']
['e (6) jungo je ɗon mari hakkeji mala jungo je ɗon mari bawɗe huwugo ngam inde je mari hakkeji. ']
['Wattinugo matinolji je woni ha ton footi waɗa jaawal ngam jaɓɓugo do ngulli maɗa.']
['Wondugo']
['Lorte ha amin be emel to a mari ƴamol/dabare.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Do ha nder']
['BioMedLib ɗon huwa be komputaji je ɗon huwa (maasinji je ɗon ekkita algorithms) ngam wurtinugo jaabolji be jaawabuji.']
['En fuɗɗan be defte bayomedikal milionji 35 je PubMed/Medline.']
